title: Sympathetic activity is not increased in L-NAME hypertensive rats.
abstract: The role played by the sympathetic drive in the development of N(G)-nitro-l-arginine methyl ester (l-NAME)-induced hypertension is not firmly established. Therefore, the present study was undertaken in conscious rats in which hypertension was induced by treatment with l-NAME over the course of either 2 or 14 days. Mean arterial pressure (MAP) was measured via a catheter placed in the femoral artery, drugs were administered via a cannula placed in the femoral vein, and renal sympathetic nerve activity (RSNA) was monitored using an implanted electrode. Despite the remarkable increase in arterial pressure, heart rate did not change after treatment with l-NAME. RSNA was similar in l-NAME-induced hypertensive rats treated over the course of 2 or 14 days, as well as in normotensive rats. It was also demonstrated that l-NAME-induced hypertensive rats displayed a resetting of the baroreflex control of RSNA to hypertensive levels, with decreased sensitivity over the course of 2 or 14 days. Furthermore, the sympathetic-vagal balance examined in the time and frequency domain and the renal and plasma norepinephrine content did not differ between groups. In conclusion, the evaluation of the sympathetic drive in conscious rats demonstrated that the arterial hypertension induced by l-NAME treatment over the course of 2 and 14 days does not show sympathetic overactivity.
authors.affiliation: Dept. of Physiology, School of Medicine of Ribeirão Preto, Univ. of São Paulo, Av. Bandeirantes, 3900, 14048-900 Ribeirão Preto-SP, Brazil.
authors.forename: Fernanda Machado
authors.initials: FM
authors.lastname: Dos Santos
authors.forename: Daniel Penteado
authors.initials: DP
authors.lastname: Martins Dias
authors.forename: Carlos Alberto Aguiar
authors.initials: CA
authors.lastname: da Silva
authors.forename: Rubens
authors.initials: R
authors.lastname: Fazan
authors.forename: Helio Cesar
authors.initials: HC
authors.lastname: Salgado
mesh_terms: D000818:Animals; D017704:Baroreflex / Q000502:physiology; D001794:Blood Pressure / Q000502:physiology; D003243:Consciousness / Q000502:physiology; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000009:adverse effects; D006339:Heart Rate / Q000502:physiology; D006973:Hypertension / Q000378:metabolism / Q000503:physiopathology*; D007668:Kidney / Q000294:innervation* / Q000378:metabolism; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology*; D009638:Norepinephrine / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013564:Sympathetic Nervous System / Q000503:physiopathology*; D013997:Time Factors
chemical_list: D004791:Enzyme Inhibitors; D019331:NG-Nitroarginine Methyl Ester; D009638:Norepinephrine